The safety of antiviral therapy and drug withdrawal for the prevention of mother-to-child transmission of HBV during pregnancy

被引:13
|
作者
Xiao, Li-Xin [1 ]
Chen, Yi-Ru [2 ]
Huang, Ping [3 ]
Mei, Yong-Yu [1 ]
Pan, Calvin Q. [4 ,5 ]
Lin, Chao-Shuang [1 ]
机构
[1] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[3] Peoples Hosp Lianjiang, Dept Infect Dis, Lianjiang, Guangdong, Peoples R China
[4] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Dept Med, Beijing, Peoples R China
[5] NYU, Dept Med, Div Gastroenterol & Hepatol, Langone Hlth,Sch Med, 132-21 41 Ave, New York, NY 11355 USA
关键词
antiviral therapy; drug withdrawal; hepatitis B virus; mother-to-child transmission; HEPATITIS-B-VIRUS; REDUCES PERINATAL TRANSMISSION; TENOFOVIR DISOPROXIL FUMARATE; SURFACE-ANTIGEN; INFECTION; EFFICACY; TELBIVUDINE; FLARES; WOMEN; PREDICTORS;
D O I
10.1002/jmv.26011
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacy of prenatal antiviral therapy (AVT) for preventing the vertical transmission of hepatitis B virus (HBV) is well demonstrated. However, data are limited regarding the safety of postpartum cessation of AVT, which may induce alanine aminotransferase (ALT) elevation. We aimed to investigate the necessity of prolonging maternal AVT after delivery. Chronic hepatitis B mothers at the immune-tolerant phase with HBV DNA levels >6 log(10) IU/mL were prospectively enrolled and received AVT during the third trimester until delivery. Patients were offered to discontinue AVT either at delivery or postpartum week (PPW) 6. In addition, mothers who deferred AVT during pregnancy served as the control group. All mothers were followed until PPW 52 for clinical and virological parameters of hepatitis flares. Among 118 mothers recruited, 91 received AVT with 53 (group A) and 24 (group B) discontinue their treatment at delivery and PPW 6, respectively. Twenty-seven mothers who deferred AVT during pregnancy were followed as the control (group C). A total of 104 of 118 mothers who completed the study, 50% (52/104) had postpartum-elevated ALT levels, which were mild and moderate except 6 of 104 (5.77%) of patients had levels >= 5 times the upper limit of normal; 70% (36/52) of the ALT flares occurred within 12 weeks after delivery. In subgroup analyses, the frequency of ALT elevation was similar among the groups A vs B vs C (50.9% [27/53] vs 58.3% [14/24] vs 40.7% [11/27], respectively;P = .447), as well as the mean peak ALT level (108.4/74.1/126.7 U/L in groups A/B/C, respectively;P = .291). Although postpartum ALT flares were common for mothers with or without AVT during pregnancy, most cases of ALT elevation were mild to moderate. Our study observed that extending AVT to PPW 6 did not affect maternal outcomes and ATV should be discontinued at birth. Close monitoring is warranted as severe flares rarely occurred.
引用
收藏
页码:3381 / 3389
页数:9
相关论文
共 50 条
  • [1] THE EFFICACY AND SAFETY OF TELBIVUDINE OR TENOFOVIR IN PREGNANCY FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HBV
    Zhang, Y.
    Wu, Q.
    Huang, H.
    Wang, Y.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S607 - S607
  • [2] Mother-to-child transmission of HBV
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (05): : 301 - 301
  • [3] Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus (HBV)
    Eke, Ahizechukwu
    Yun, Xia
    Eke, Uzoamaka
    Eleje, George
    Jiao, Liu
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 210 (01) : S226 - S226
  • [4] Prevention of Mother-To-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy
    Harlfinger, Julia
    Nussbaumer-Streit, Barbara
    Gartlehner, Gerald
    GESUNDHEITSWESEN, 2023, 85 (04) : 266 - 269
  • [5] Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy
    Lockman, Shahin
    CURRENT OPINION IN HIV AND AIDS, 2008, 3 (02) : 166 - 172
  • [6] Mechanism and Antiviral Therapy in Preventing Mother-to-Child Transmission During Pregnancy with Hepatitis B Virus Infection
    Zhao, Mengyu
    Zou, Huaibin
    Chen, Yu
    Duan, Zhongping
    HEPATITIS MONTHLY, 2019, 19 (10)
  • [7] Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: Current standards of care
    Giles, Michelle L.
    Grace, Ruth
    Tai, Amy
    Michalak, Katarzyna
    Walker, Susan P.
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2013, 53 (03): : 231 - 235
  • [8] Preventing mother-to-child transmission of HBV
    Lu, Qing-Bin
    Cui, Fuqiang
    LANCET INFECTIOUS DISEASES, 2022, 22 (08): : 1096 - +
  • [9] Prevention of mother-to-child transmission
    Surjushe, Amar
    Maniar, Janak
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2008, 74 (03): : 200 - 207
  • [10] HIV testing during pregnancy for prevention of mother-to-child transmission of HIV in Ethiopia
    Ejigu, Yohannes
    Tadesse, Biniyam
    PLOS ONE, 2018, 13 (08):